Patents Assigned to Boehringer Ingelheim International GmbH
  • Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors
    Patent number: 10898487
    Abstract: The present invention encompasses compounds of formula (I), wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: January 26, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Kessler, Christiane Kofink, Matthew Russell Netherton, Juergen Ramharter, Tobias Wunberg
  • Nebulizer and container
    Patent number: 10898661
    Abstract: A nebulizer as well as a container with a fluid for such a nebulizer are proposed. The container comprises a control device which indicates initially an unused state of the container before first use. An indicator device stops via a locking device further use of the container in a locked state when a predetermined number of uses has been reached or exceeded. After replacement of the container, the nebulizer can be reset and used again.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: January 26, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Andree Jung
  • Selective enrichment of antibodies
    Patent number: 10894806
    Abstract: The invention relates to a process for the selective concentration of immunoglobulins or other proteins that contain an Fc domain (target protein), comprising the following steps: a. preparing a solution that contains the target protein; b. incorporating an Fc-binding protein with precisely two binding sites under conditions that allow binding to occur; c. separating the precipitate from the liquid phase; d. undoing the binding of the target protein from the Fc-binding protein.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: January 19, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dorothee Ambrosius, Michael Dieterle, Philine Dobberthien, Maria-Katharina Wiegeshoff
  • Nebulizer
    Patent number: 10894134
    Abstract: A nebulizer is proposed which comprises a blocking device for blocking opening of the nebulizer in a tensioned state. The nebulizer comprises preferably an indicator device for indicating a tensioned state of the nebulizer. The nebulizer comprises further a depressible actuator member at a housing part which is detachable from the nebulizer.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: January 19, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jens Besseler, Frank Herrmann, Holger Holakovsky, Herbert Argauer, Josef Gatz, Andreas Gorshoefer
  • Inhibitors of TRPC6
    Patent number: 10889568
    Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: January 12, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • Spiro[3H-indole-3,2?-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
    Patent number: 10882866
    Abstract: The present invention encompasses intermediates for preparing compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: January 5, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gollner, Joachim Broeker, Nina Kerres, Christiane Kofink, Juergen Ramharter, Harald Weinstabl, Annika Gille, Stefan Goepper, Manuel Henry, Guenther Huchler
  • Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide
    Patent number: 10875867
    Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: December 29, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christoph Hoenke, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Sara Frattini, Riccardo Giovannini, Scott Hobson
  • Heteroaromatic compounds as BTK inhibitors
    Patent number: 10875852
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: December 29, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Joerg Bentzien, Angela Kay Berry, Todd Bosanac, Michael Jason Burke, Darren Todd Disalvo, Joshua Courtney Horan, Shuang Liang, Can Mao, Wang Mao, Yue Shen, Fariba Soleymanzadeh, Renee M. Zindell
  • Heteroaromatic compounds as Vanin inhibitors
    Patent number: 10864201
    Abstract: The present invention encompasses compounds of the formula I which are suitable for the treatment of diseases related to Vanin, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: December 15, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Cédrickx Godbout, Martin Thomas Fleck, Hannes Fiepko Koolman
  • Method for forming and/or testing a bag in the interior space of a container
    Patent number: 10859463
    Abstract: The present invention relates to a method for producing a bag in the interior space of a container and for testing said bag, and to a system for this purpose, to a computer program product for execution, and to the use of the system for the methods.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: December 8, 2020
    Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Gerald Mathe, Carlos-Manuel Costa Pereira-Kirchwehm
  • Mammalian cells for producing a secreted protein
    Patent number: 10858653
    Abstract: The invention relates to the field of cell culture technology. It concerns the knockdown, using RNA interference, or gene knockout, of activating transcription factor 6 beta (ATF6B), or the combination of ceramide synthase 2 (CERS2) and TBC1 domain family member 20 (TBC1 D20) proteins, which play central roles in the cellular secretion pathway. This downregulation leads to improved secretion of biopharmaceutically relevant products produced in mammalian cells. The invention specifically relates to mammalian cells having enhanced secretion of a recombinant therapeutic protein compared to a control cell, a method of producing said mammalian cell, a method for the production of a recombinant secreted therapeutic protein and the use of said mammalian cell for increasing the yield of a recombinant secreted therapeutic protein.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: December 8, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Monilola Olayioye, Angelika Hausser, Lisa Pieper, Michaela Strotbek, Till Wenger
  • Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases
    Patent number: 10858342
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: December 8, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Michael Balestra, Jennifer Burke, Zhidong Chen, Derek Cogan, John Lord, Daniel Richard Marshall, Bryan P. McKibben, Kenneth M. Meyers, Yunlong Zhang
  • TRAILR2 CDH17 binding molecules for the treatment of cancer
    Patent number: 10858438
    Abstract: This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: December 8, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus-Peter Kuenkele, Timothy Fenn, Juan Manuel Garcia-Martinez, Jason Ho, Christian Koessl, Saurabh Sen, Vladimir Voynov, Andreas Wernitznig
  • BIOMARKERS USEFUL IN THE TREATMENT OF IL-23A RELATED DISEASES
    Publication number: 20200376117
    Abstract: This invention generally relates to biomarkers useful in the treatment of IL-23 related diseases, in particular inflammatory diseases such as psoriasis. The invention also relates to methods of using the biomarkers disclosed herein, for example in therapies utilizing IL-23 antagonists.
    Type: Application
    Filed: December 10, 2019
    Publication date: December 3, 2020
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Sudha Visvanathan, Patrick Baum, Oliver Kleiner, Ulrich Kunz
  • Imidazopyridine derivatives and the use thereof as medicament
    Patent number: 10849907
    Abstract: The present invention relates to imidazopyridines of formula A processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: December 1, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Georg Dahmann, Cornelia Dorner-Ciossek, Lothar Kussmaul, Roland Pfau, Dieter Wiedenmayer
  • Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof
    Patent number: 10844138
    Abstract: The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: November 24, 2020
    Assignees: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, MACROGENICS, INC.
    Inventors: Sanjaya Singh, Qi Pan, Rachel Rebecca Barrett, Leslie S. Johnson, Pankaj Gupta, Sarah Low, Haixia Wu
  • Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors
    Patent number: 10829487
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: November 10, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Juergen Ramharter, Christiane Kofink, Heinz Stadtmueller, Tobias Wunberg
  • Inhibitors of TRPC6
    Patent number: 10800757
    Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: October 13, 2020
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • Bundle with different information leaflets and method for producing such a bundle
    Patent number: 10793330
    Abstract: A method for producing a bundle (2) of different information leaflets (3, 4) from a sheet of flat material having at least two different sections, and a bundle (2) of such leaflets. The information leaflets (3, 4) are folded jointly and a protruding fold (14) is cut for separation of the information leaflets (3, 4).
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: October 6, 2020
    Assignees: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, EUKERDRUCK GMBH & CO. KG
    Inventors: Michal Rachel Bokovza, Robert Maegerlein, Thorsten Csellner
  • Anti-TrkB antibodies
    Patent number: 10793634
    Abstract: The present invention relates to novel agonistic anti-TrkB antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: October 6, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rolf Herrmann, Remko Alexander Bakker, Sebastian Bandholtz, Peter Michael Benz, Michael Dziegelewski, Lore Florin, Cynthia Hess Kenny, Sarah Low, Holger Rosenbrock, Sanjaya Singh, Heiko Friedrich Stahl, Sathyadevi Venkataramani, Vladimir Voynov, Haiguang Xiao